Skip to main content

Myeloma Therapy

Genes Highlight Who'll Benefit From Multiple Myeloma Therapy


Genetic tests can show which patients with the blood cancer multiple myeloma should respond to targeted therapy, a new study finds.

A special six-gene pattern can help predict who are more likely to respond well to Venclexta (venetoclax), a pill that promotes natural cell death among cancer cells, researchers said.

“By knowing which patients might benefit the most, we can customize treatments to improve their chances of success,” said researcher Alessandro Lagana, an assistant professor of oncological sciences at the Icahn School of Medicine at Mount Sinai, in New York City.

Multiple myeloma is a cancer of blood plasma cells, according to the American Cancer Society. About 35,780 new cases of multiple myeloma are expected to be diagnosed in 2024, and it will kill about 12,540 U.S. adults.

Venclexta keeps cancer cells from dodging apoptosis, the body process that causes old or damaged cells to self-destruct.

Multiple myeloma cells carry a protein called BCL-2 that keeps the cell from triggering apoptosis. Venclexta inhibits BCL-2, restoring natural cell death for these cancer cells.

The U.S. Food and Drug Administration approved Venclexta in 2018, but up to now it’s been unclear which patients would most benefit from the drug.

For this study, researchers analyzed the genetics of 58 patients treated with Venclexta between 2017 and 2021.

They discovered a specific genetic pattern “with higher scores being consistently associated with less favorable responses,” the research team wrote.

“Doctors could use genetic testing to choose the best candidates for venetoclax treatment,” Lagana said in a Icahn news release.

Researchers also found that Venclexta worked best when paired with a CKD7 inhibitor, another type of drug that promotes natural cell death.

“Combining venetoclax with CDK7 inhibitors might help more patients respond positively,especially those who might not respond well to venetoclax alone,” Lagana said. “For patients, this research means someday they could receive more personalized treatment plans based on their genetic information, leading to better outcomes.”

Researchers next plan to confirm their findings in a larger group of patients, and to test the combined use of Venclexta and CDK7 inhibitors in clinical trials.

The new study was published in December issue of the journal Blood Neoplasia.

Multiple myeloma, myeloma therapy, plasma cell neoplasm, monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs, CAR-T cell therapy, bispecific antibodies, autologous stem cell transplant, minimal residual disease, amyloidosis, lenalidomide, bortezomib, daratumumab, pomalidomide, selinexor, elotuzumab, ixazomib, Venetoclax, dexamethasone, alkylating agents, cytokine release syndrome, relapse, refractory myeloma, personalized medicine.

#MultipleMyeloma, #MyelomaTherapy, #CancerTreatment, #PlasmaCellNeoplasm, #MonoclonalAntibodies, #ProteasomeInhibitors, #Immunotherapy, #CAR_T, #StemCellTransplant, #MinimalResidualDisease, #Amyloidosis, #Lenalidomide, #Bortezomib, #Daratumumab, #Pomalidomide, #Selinexor, #Elotuzumab, #Ixazomib, #Venetoclax, #Dexamethasone, #OncologyResearch, #RelapseMyeloma, #RefractoryMyeloma, #PrecisionMedicine, #CancerAwareness.

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more